Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1465003 | 0.81 | KMT2A (0.50) | KMT2AAKR1C1MEN1ALDH1A1 | |
| SCHEMBL10083737 | 0.81 | KMT2A (0.50) | KMT2AAKR1C1MEN1CYP2C19 | |
| SCHEMBL15547234 | 0.78 | AKR1C1 (0.53) | KMT2AAKR1C1AKR1C3ALDH1A1 | |
| SCHEMBL10083308 | 0.77 | KMT2A (0.50) | KMT2AAKR1C1MEN1CYP2C19AKR1C3 | |
| SCHEMBL521247 | 0.76 | AKR1C1 (0.54) | KMT2AAKR1C1MEN1ALDH1A1 | |
| SCHEMBL7467608 | 0.76 | AKR1C1 (0.59) | KMT2AAKR1C1MEN1ALDH1A1 | |
| SCHEMBL21874215 | 0.75 | KDM1A (0.49) | KMT2AAKR1C1MEN1ALDH1A1 | |
| SCHEMBL21826168 | 0.75 | HDAC3 (0.48) | KMT2AAKR1C1AKR1C3AKR1C2 | |
| SCHEMBL8587542 | 0.75 | AKR1C1 (0.57) | KMT2AAKR1C1MEN1ALDH1A1 | |
| SCHEMBL10083000 | 0.73 | ALDH1A1 (0.55) | AKR1C1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303027-B2 | Kappa opioid receptor agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-04-05 | — | — | US | disclosed |
| US-9303027-B2 | Kappa opioid receptor agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-04-05 | — | — | US | disclosed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012012410-A2 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OPRD1 | KMT2A 1079/4885AKR1C1 494/4885FAAH 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.